Health-related quality of life questionnaires in lung cancer trials: A systematic literature review

Health Economics Review

Volumn 3, Issue 1, 2013, Pages 1-10

  Damm, Kathrin ^a   Roeske, Nicole ^a   Jacob, Christian ^b  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b Herescon GmbH   (Germany)

Author keywords

Health economics; Health related quality of life; Lung cancer; Questionnaires; Utility measurement

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMIFOSTINE; CARBOPLATIN; CHINESE DRUG; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOFOS; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GEMCITABINE; GENERIC DRUG; IFOSFAMIDE; IRINOTECAN; MEGESTROL ACETATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; REBIMASTAT; SHENFU; TOPOTECAN; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

ADVANCED CANCER; BRIEF PAIN INDEX; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DIET THERAPY; ELECTRONIC MEDICAL RECORD; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER LC13 QUESTIONNAIRE; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QLQ C30 QUESTIONNAIRE; FEIJI RECIPE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GENERAL QUESTIONNAIRE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY LUNG QUESTIONNAIRE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LUNG CANCER; LUNG CANCER SYMPTOM SCALE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SURGERY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; REVIEW; SYSTEMATIC REVIEW;

EID: 84971222653     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/2191-1991-3-15     Document Type: Review

References (55)

1. Robert Koch Institut: Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V: Krebs in Deutschland 2005/2006. Berlin: Häufigkeiten und Trends; 2010.
2. Reck M: Quality of life as an endpoint of clinical trials. Lung Cancer 2009, 64(Suppl 1):22-23.
3. Liu J, Mittendorf T, von der Schulenburg JM: A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia. Cancer Invest 2010, 28:312-322.
4. Camps C, del Pozo N, Blasco A, Blasco P, Sirera R: Importance of quality of life in patients with Non-small-cell lung cancer. Clin Lung Cancer 2009, 10:83-90.
5. Schöffski O: Lebensqualität als Ergebnisparameter in gesundheitsökonomischen Studien. In Gesundheitsökonomische Evaluationen. Edited by Schöffski O, Von der Schulenburg JM. Berlin: Heidelberg: Springer; 2007:321-334.
6. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:332-336.
7. Agteresch HJ, Rietveld T, Kerkhofs LG, van den Berg JW, Wilson JH, Dagnelie PC: Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. J Clin Oncol 2002, 20:371-378.
8. Baka S, Ashcroft L, Anderson H, Lind M, Burt P, Stout R, Dowd I, Smith D, Lorigan P, Thatcher N: Randomized phase II study of Two gemcitabine schedules for patients with impaired performance status (karnofsky performance status 70) and advanced Non-small-cell lung cancer. J Clin Oncol 2005, 23:2136-2144.
9. Belani CP, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Fossella F, TAX 326 study group: Effect of chemotherapy for advanced Non-small cell lung cancer on Patients' quality of life - a randomized controlled trial. Lung Cancer 2006, 53:231-239.
10. Bezjak A, Lee CW, Ding K, Brundage M, Winton T, Graham B, Whitehead M, Johnson DH, Livingston RB, Seymour L, Shepherd FA: Quality-of-life outcomes for adjuvant chemotherapy in early-stage Non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol 2008, 26:5052-5059.
11. Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton D, Von Pawel J, Reck M, Shepherd FA, National Cancer Institute of Canada Clinical Trials Group Study BR.21: Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the national cancer institute of Canada clinical trials group study BR.21. J Clin Oncol 2006, 24:3831-3837.
12. Bianco V, Di Girolamo B, Pignatelli E, Speranza I, Florio G, Gemma D, Girolami M, Vietri F, Marchei P: Gemcitabine as single agent therapy in advanced Non small-cell lung cancer and quality of life in the elderly. Panminerva Med 2001, 43:15-19.
13. Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M, O'Brien M, Dunlop D, O'Byrne K, Laurence V, Snee M, Dark G, Thatcher N: A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced Non-small-cell lung cancer: a randomised multicenter trial of the british thoracic oncology group (BTOG1). Ann Oncol 2006, 17:1111-1119.
14. Bozcuk H, Dalmis B, Samur M, Ozdogan M, Artac M, Savas B: Quality of life in patients with advanced Non-small cell lung cancer. Cancer Nurs 2006, 29:104-110.
15. Brown J, Thorpe H, Napp V, Fairlamb DJ, Gower NH, Milroy R, Parmar MK, Rudd RM, Spiro SG, Stephens RJ, Waller D, West P, Peake MD: Assessment of quality of life in the supportive care setting of the Big lung trial in Non-small-cell lung cancer. J Clin Oncol 2005, 23:7417-7424.
16. Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Heyes A, Ochs JS, Wolf MK, Kay AC, Kris MG, Natale RB: Clinically meaningful improvement in symptoms and quality of life for patients with Non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 2005, 23:2946-2954.
17. Chen ML, Yu CT, Yang CH: Sleep disturbances and quality of life in lung cancer patients undergoing chemotherapy. Lung Cancer 2008, 62:391-400.
18. Dancey J, Shepherd FA, Gralla RJ, Kim YS: Quality of life assessment of second-line docetaxel versus best supportive care in patients with Non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004,43:183-194.
19. de Marinis F, Pereira JR, Fossella F, Perry MC, Reck M, Salzberg M, Jassem J, Peterson P, Liepa AM, Moore P, Gralla RJ: Lung cancer symptom scale outcomes in relation to standard efficacy measures - an analysis of the phase III study of pemetrexed versus docetaxel in advanced Non-small cell lung cancer. J Thorac Oncol 2008, 3:30-36
20. Gelibter A, Ceribelli A, Pollera CF, Milella M, Moscetti L, Sperduti I, Cognetti F: Impact of gefitinib ('Iressa') treatment on the quality of life of patients with advanced non-small-cell lung cancer. J Cancer Res Clin Oncol 2005, 131:783-788.
21. Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F: Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced Non-small cell lung cancer: a phase III trial of the Italian GEMVIN investigators and the national cancer institute of Canada clinical trials group. J Clin Oncol 2003, 213025-213034
22. Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S: Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced Non-small-cell lung cancer. J Clin Oncol 2009, 27:3217-3224.
23. Helbekkmo N, Strøm HH, Sundstrøm SH, Aasebø U, Von Plessen C, Bremnes RM, Norwegian Lung Cancer Study Group: Chemotherapy and quality of life in NSCLC PS 2 patients. Acta Oncol 2009, 28:1019-1025
24. Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA: The impact of Age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003, 98:779-788
25. LeCaer H, Delhoume JY, Thomas PA, Berard H, Paillotin D, Barriere JR, Gimenez C, Vergnenegre A, Muller P, Auquier P, Perol M: Multicenter phase II trial of carboplatin/vinorelbine in elderly patients with advanced Non-small-cell lung cancer-efficacy and impact on quality of life: groupe français de pneumo-cancérologie study 9902. Clin Lung Cancer 2005, 7:114-120.
26. Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A, Humphrey JS, Voi M, Galbraith S, Hann K, Seymour L, Shepherd FA: Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced Non-small-cell lung cancer: national cancer institute of Canada-clinical trials group study BR.18. J Clin Oncol 2005, 23:2831-2839
27. Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, Witt K, Botkin D: Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008, 26:863-869
28. Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati SF, Bertetto O, Novello S, Migliorino MR, Favaretto A, Spatafora M, Ferraù F, Frontini L, Bearz A, Repetto L, Gridelli C, Barletta E, Barzelloni ML, Iaffaioli RV, De Maio E, Di Maio M, De Feo G, Sigoriello G, Chiodini P, Cioffi A, Guardasole V, et al: Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced Non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 2005, 23:6865-6872
29. McQuellon RP, Moose DB, Russell GB, Case LD, Greven K, Stevens M, Shaw EG: Supportive Use of magestrol acetate (megace) with head/neck and lung cancer patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 2002, 52:1180-1185.
30. Mohan A, Singh P, Kumar S, Mohan C, Pathak AK, Pandey RM, Guleria R: Effect of change in symptoms, respiratory status, nutritional profile and quality of life on response to treatment for advanced Non-small cell lung cancer. Asian Pac J Cancer Prev 2008, 9:557-562.
31. Moinpour CM, Lyons B, Grevstad PK, Lovato LC, Crowley J, Czaplicki K, Buckner ZM, Ganz PA, Kelly K, Gandara DR: Quality of life in advanced Non-small-cell lung cancer: results of a southwest oncology group randomized trial. Qual Life Res 2002, 11:115-126.
32. Morita S, Kobayashi K, Eguchi K, Matsumoto T, Shibuya M, Yamaji Y, Sakamoto J, Ohashi Y: Influence of clinical parameters on quality of life during chemotherapy in patients with advanced Non-small cell lung cancer: application of a general linear model. Jpn J Clin Oncol 2003, 33:470-476.
33. Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T, Byhardt R: Randomized trial of amifostine in locally advanced Non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 2005, 23:2145-2154.
34. Mu XL, Li LY, Zhang XT, Wang SL, Wang MZ: Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme. BMC Cancer 2004, 4:1-8.
35. Natale RB: Effects of ZD1839 (iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced Non-small cell lung cancer. Semin Oncol 2004, 31:23-30
36. O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G, Thatcher N, Ross GA, Dane GC, Crofts T: Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006, 24:5441-5447
37. Paccagnella A, Favaretto A, Oniga F, Barbieri F, Ceresoli G, Torri W, Villa E, Verusio C, Cetto GL, Santo A, De Pangher V, Artioli F, Cacciani GC, Parodi G, Soresi F, Ghi MG, Morabito A, Biason R, Giusto M, Mosconi P, Chiarion Sileni V, GSTVP (Gruppo di Studio Tumori Polmonari del Veneto): Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced Non-small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 2004, 43:83-91
38. Pijls-Johannesma M, Houben R, Boersma L: High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL. Radiother Oncol 2009, 91443-448
39. Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R, Ulm K, Hessler S, Gatzemeier U: Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-Years'-follow-Up results from a randomised phase III trial. Lung Cancer 2006, 53:67-75.
40. Sarna L, Swann S, Langer C: Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced Non-small cell lung cancer: an analysis of RTOG 9801. Int J Radiat Oncol Biol Phys 2008, 72:1378-1384.
41. Schumacher A, Riesenbeck D, Braunheim M, Wewers D, Heinecke A, Semik M, Hoffknecht P, Macha HN, Klinke F, Schmidt EW, Willich N, Berdel WE, Thomas M, German Lung Cancer Cooperative Group: Combined modality treatment for locally advanced Non-small cell lung cancer: preoperative chemoradiation does Not result in a poorer quality of life. Lung Cancer 2004, 44:89-97.
42. Sekine I, Ichinose Y, Nishiwaki Y, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Itoh Y, Tamura T, Saijo N, Fukuoka M: Quality of life and disease-related symptoms in previously treated Japanese patients with Non-small cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol 2009, 20:1483-1488.
43. Sirisinha T, Sirilertrakul S, Jirajarus M, Ratanatharathorn V Doxetaxel in previously treated Non-small cell lung cancer patients: clinical efficacy and quality of life. Southeast Asian J Trop Med Public Health 2005, 36:246-253.
44. Thatcher N, Qian W, Clark PI, Hopwood P, Sambrook RJ, Owens R, Stephens RJ, Girling DJ: Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British medical research council multicenter randomized LU21 trial. J Clin Oncol 2005, 23:8371-8379.
45. Tian JH, Liu LS, Shi ZM, Zhou ZY, Wang L: A randomized controlled pilot trial of "feiji recipe" on quality of life of Non-small cell lung cancer patients. Am J Chin Med 2010, 38:15-25
46. Vilmar A, Santoni-Rugiu E, Sørensen JB: ERCC1, Toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer 2010, 46:1554-1562.
47. Von Plessen C, Bergman B, Andresen O, Bremnes RM, Sundstrom S, Gilleryd M, Stephens R, Vilsvik J, Aasebo U, Sorenson S: Palliative chemotherapy beyond three courses conveys No survival or consistent quality-of-life benefits in advanced Non-small cell lung cancer. Br J Cancer 2006, 95:966-973.
48. Wu WY, Long SQ, Zhang HB, Chai XS, Deng H, Xue XG, Wang B, Luo HY, Liu WS: Improvement of quality of life with shenfu injection in Non small-cell lung cancer patients treated with gemcitabine plus cisplatin regimen. Chin J Integr Med 2006, 12:50-54.
49. Zhang XT, Li LY, Wang SL, Mu XL, Wang MZ, Song W: Improvements in quality of life and disease-related symptoms in patients with advanced Non-small cell lung cancer treated with gefitinib. Chin Med J 2005, 118:1661-1664.
50. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Stein Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F: The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
51. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J: The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993, 11:570-579.
52. PROQOLID - Patient-Reported Outcome and Quality of life Instruments Database http://www.proqolid.org/.
53. Damm K, Jacob C, Mittendorf T, von der Schulenburg JM: Lebensqualitätsmessung in klinischen Studien beim Lungenkarzinom -Übersicht anhand der Datenbank ClinicalTrials.gov [Measuring Health Related Quality of Life in Lung Cancer Clinical Trials - An Overview of the Database ClinicalTrials.gov]. PharmacoEconomics - German Research Articles 2012,10:3-15.
54. Salvo N, Hadi S, Napolskikh J, Goh P, Sinclair E, Chow E: Quality of life measurement in cancer patients recieving palliative radiotherapy for symptomatic lung cancer: a literature review. Current Oncology 2009, 16:16-28.
55. Montazeri A, Gillis CR, McEwen J: Quality of life in patients with lung cancer: a review of literature from 1970 to 1995. Chest 1998, 113:467-481